Header

Gastrointestinal Malignancies Clinical Trials

Category:Adult
Status:Active

Displaying Trial 1 - 30 of 66 in total

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be ran...

Diagnosis: Gastrointestinal Malignancies, Liver Cancer

Phase: 3

Protocol Number: 15-287

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with p...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase: 3

Protocol Number: 16-146

Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer

The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Diagnosis: Esophageal Cancer, Gastrointestinal Malignancies

Phase: 3

Protocol Number: 16-197

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

This research study is a Phase II clinical trial to test the safety and effectiveness of the investigational drug Ziv-aflibercept in combination with mFOLFOX6 compared to mFOLFOX6 alone. The drugs ...

Diagnosis: Gastrointestinal Malignancies, Esophageal Cancer, Stomach Cancer

Phase: 2

Protocol Number: 12-401

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational combination of drugs to learn whether the drug combination works in treating ...

Diagnosis: Gastrointestinal Malignancies, Liver Cancer

Phase: 2

Protocol Number: 12-218

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigat...

Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid

Phase: 2

Protocol Number: 12-456

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.

Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 16-072

Pembrolizumab in Refractory Metastatic Anal Cancer

This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab

Diagnosis: Gastrointestinal Malignancies

Phase: 2

Protocol Number: 16-301

Gemcitabine Plus BPM31510 Administered Intravenously in Advanced Pancreatic Cancer Patients

This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of the combination of BPM31510 administered as a 144-hour continuous intravenous (IV) infusio...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase: 2

Protocol Number: 17-066

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. Th...

Diagnosis: Gastrointestinal Malignancies, Peritoneal Cancer, Colorectal Cancer

Phase: 2

Protocol Number: 17-177

A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)

The purpose of this study is to examine if Nivolumab alone, Nivolumab in combination with Ipilimumab, or Nivolumab in combination with Ipilimumab and Cobimetinib will demonstrate a meaningful objec...

Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer

Phase: 1 / 2

Protocol Number: 14-166

Safety and Efficacy of FGF401 in Patients With Solid Malignancies

Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies

Diagnosis: Gastrointestinal Malignancies, Stomach Cancer, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer

Phase: 1 / 2

Protocol Number: 14-464

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocr...

Diagnosis: Neuroendocrine/Carcinoid, Gastrointestinal Malignancies

Phase: 1 / 2

Protocol Number: 16-450

A Study of DKN-01 in Combination With Paclitaxel

A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel in participants with refractory/recurrent esophageal or gastro-esophageal junction cancer.

Diagnosis: Gastrointestinal Malignancies

Phase: 1

Protocol Number: 14-004

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) of MGD007 administered on either weekly or every three...

Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer

Phase: 1

Protocol Number: 14-524

A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer

This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refract...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer, Colorectal Cancer

Phase: 1

Protocol Number: 17-137

Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.

This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the ...

Diagnosis: Gastrointestinal Malignancies, Colorectal Cancer

Phase: 0

Protocol Number: 14-091

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Undergoing Surgery

This pilot clinical trial studies the best dose of erlotinib hydrochloride and to see how well it works in preventing liver cancer in patients with scarring (cirrhosis) of the liver undergoing surg...

Diagnosis: Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 14-333

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer. The sponsor of this protocol is the Massachusetts General...

Diagnosis: Breast: Early Stage Disease, Lung Cancer, Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 16-230

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

This research study is studying the Surefire Infusion System ("Surefire") for increasing delivery of chemotherapeutic agents delivered trans-arterially to intermediate stage Hepatocellula...

Diagnosis: Liver Cancer, Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 16-077

Improving Informed Consent for Palliative Chemotherapy

Patients are routinely asked to sign an "informed consent" document prior to starting chemotherapy, indicating they understand the risks and benefits of treatment. Although this could be ...

Diagnosis: Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 15-143

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sora...

Diagnosis: Gastrointestinal Malignancies

Phase:

Protocol Number: 15-108

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Pr...

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 15-191

Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of ...

Diagnosis: Gastrointestinal Malignancies, Neuroendocrine/Carcinoid

Phase:

Protocol Number: 16-705

A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of BLU...

Diagnosis: Liver Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 16-076

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)

This study will assess the efficacy and safety of BL-8040 as a single agent and in combination with pembrolizumab (Keytruda®) in subjects with metastatic pancreatic adenocarcinoma.

Diagnosis: Pancreatic Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 16-508

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surg...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 16-490

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiation prior to surgery. This study will allow the researchers to know whether...

Diagnosis: Gastrointestinal Malignancies, Pancreatic Cancer

Phase:

Protocol Number: 17-047

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared ...

Diagnosis: Stomach Cancer, Gastrointestinal Malignancies

Phase:

Protocol Number: 16-566

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

This research study is designed to evaluate a type of scan called Ga-68-DOTA-TOC positron emission tomography (PET) scanning as a way of assessing carcinoid tumors.

Diagnosis: Gastrointestinal Malignancies

Phase:

Protocol Number: 16-193

<< Previous 1 3
'